Literature DB >> 24929753

Progressive multifocal leukoencephalopathy complicating untreated chronic lymphatic leukemia: case report and review of the literature.

Franziska Di Pauli1, Thomas Berger2, Alois Walder3, Hans Maier4, Paul Rhomberg5, Christian Uprimny6, Michael Steurer7, Guenther Stockhammer2.   

Abstract

A 58-year old female with a four-year history of previously untreated CLL at Binet stage A complained about word finding problems, impaired vision, and gait unsteadiness. Concerning her CLL she was asymptomatic and had never required any specific treatment. Her neurological examination disclosed cognitive alterations, homonyme hemianopia to the right, aphasia, and mild right-sided hemiparesis. Cerebral MRI showed a hyperintense lesion on T2 weighted images without contrast enhancement. CSF examination revealed normal findings, including CSF protein, cell count, cytology and PCR-analysis was negative for the presence of JC virus DNA. On follow-up MRI, performed 2 weeks later, the T2 lesion was further enlarging. Subsequent stereotactic brain biopsy was diagnostic for PML revealing abnormal oligodendrocytes staining positive against antibodies specific for simian vacuolating virus 40. In addition, repeated CSF analyses for JC-Virus DNA in the course of the disease became positive. After confirmation of diagnosis treatment with mirtazapine (30 mg/d) and mefloquine (250 mg/d) was initiated. Rapid clinical progression correlated to further worsening on MRI. Therefore this treatment was terminated after 16 days and the regime was changed to a five-day courses of cytarabine (2 mg/kg/d) combined with intrathecal administration of liposomal cytarabine (50 mg). Due to further clinical progression with global aphasia, blindness and severe right-sided hemiparesia, medication was stopped. The Patient died three and a half months after onset of symptoms.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chronic lymphatic leukemia; JC Virus; Progressive multifocal leukoencephalopathy

Mesh:

Substances:

Year:  2014        PMID: 24929753     DOI: 10.1016/j.jcv.2014.05.007

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  3 in total

1.  A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).

Authors:  Clive S Zent; Xin Victoria Wang; Rhett P Ketterling; Curtis A Hanson; Edward N Libby; Jacqueline C Barrientos; Timothy G Call; Julie E Chang; Jane J Liu; Alejandro R Calvo; Hillard M Lazarus; Jacob M Rowe; Selina M Luger; Mark R Litzow; Martin S Tallman
Journal:  Am J Hematol       Date:  2016-02-09       Impact factor: 10.047

2.  Not All Strokes Are Strokes An Example of Diagnostic Confirmation Bias.

Authors:  Melanie Dani; Sophie Bowen-Carpenter; Patrick J McGown
Journal:  Eur J Case Rep Intern Med       Date:  2019-01-08

Review 3.  The Use of Antimalarial Drugs against Viral Infection.

Authors:  Sarah D'Alessandro; Diletta Scaccabarozzi; Lucia Signorini; Federica Perego; Denise P Ilboudo; Pasquale Ferrante; Serena Delbue
Journal:  Microorganisms       Date:  2020-01-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.